Amplia Therapeutics Analysis in April (2026) | Price Target, Profits & Valuation

Amplia Therapeutics

ASX:ATX

$ 0,16

$0,00 (0,00%)

0,16 $

$0,00 (0,00%)

End-of-day quote: 04/13/2026

Amplia Therapeutics Stock Value

Analysts currently give ASX:ATX a rating of Buy.

Buy

Amplia Therapeutics Company Info

EPS Growth 5Y

0,00%

Market Cap

$0,08 B

Long-Term Debt

$0,00 B

Annual earnings

05/29/2026 (E)

Dividend

$0,00

Dividend Yield

0,00%

Founded

2000

Industry

Health Care

Country

Australia

Website

Amplia Therapeutics

ISIN Number

AU0000023822

Website

http://www.ampliatx.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

$0,42

162.5%

Last Update: 04/13/2026

Analysts: 1

Highest Price Target $0,42

Average Price Target $0,42

Lowest Price Target $0,42

In the last five quarters, Amplia Therapeutics’s Price Target has risen from $4,17 to $7,30 - a 75,06% increase. One analysts predict that Amplia Therapeutics’s share price will increase in the coming year, reaching $0,42. This would represent an increase of 162,50%.

Top growth stocks in the health care sector (5Y.)

What does Amplia Therapeutics do?

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer, other solid tumors, other fibrotic disease, and scar reduction which is in clinical trial. Business Segments The company op...

Business Segments

The company operates with a singular focus on the biotechnology sector, specializing in the development of targeted therapeutics. The company’s internal resources are dedicated to research and development efforts, aligning with its strategy to pioneer drug candidates that address unmet medical needs. While it currently does not have various operating segments, the organization's concentration on a limited number of drug candidates enables effective allocation of resources and transparency around progress and outcomes.

Business Strategy

The company’ business strategy revolves around its strong commitment to excellence in drug development, with a clear focus on bringing novel therapies to market that address significant unmet clinical needs. The company believes that its rigorous R&D processes, including preclinical testing and validation, will foster a competitive advantage in the biotechnology field.

To enhance its strategic positioning, the company intends to pursue collaborations and partnerships with established academic institutions and other industry players to leverage their expertise and resources. Such strategic alliances can accelerate the development timelines of drug candidates and increase the potential for successful commercialization.

The company’s strategic emphasis is also on safeguarding its intellectual property (IP), a critical facet that can distinguish its drug candidates in the crowded biotechnology landscape. The company recognizes the necessity of protecting its discoveries and innovations to ensure competitive advantage and secure funding essential for continued development efforts.

Moreover, due to the capital-intensive nature of the biotechnology industry, the company is focused on establishing efficient financial management practices. This stability is crucial not only for managing operational costs but also for attracting potential investors who are looking for companies with sound financial strategies in the biopharmaceutical space.

Products and Services

The company is primarily focused on the discovery and development of advanced therapeutics targeting severe health conditions. Although the company has not yet commercialized any products, its pipeline consists of promising drug candidates advancing through preclinical development stages. The primary objective of the company Therapeutics is to develop therapies that harness specific biological pathways with demonstrated efficacy in treating complex diseases. The company invests considerable effort into understanding the pharmacological profiles and safety profiles of its drug candidates. This involves extensive laboratory testing and collaboration with recognized research organizations to ensure the credibility and viability of its potential therapies.

Geographical Markets Served

The company is currently focused on the Australian market, where it conducts all its research and development activities and aims to establish its market presence. The biotechnology landscape in Australia provides a conducive environment for research and innovation, aligning with Amplia Therapeutics’ mission to develop advanced therapeutics.

Customers

The company’s target market primarily consists of patients suffering from severe diseases that the developed therapies aim to address. However, it envisions building relationships with healthcare professionals and institutions in the future as its drug candidates advance toward clinical trials and potential market entry.

Marketing/Distribution Channels

The company has not yet commercialized any products and thus does not currently engage in sales, marketing, or distribution activities. The focus remains solely on research and development, with marketing strategies expected to be designed and implemented once the company progresses into the commercialization phase.

Regulations

Regulatory bodies, including the Therapeutic Goods Administration (TGA) in Australia, dictate the standards and practices that must be followed to ensure safety, efficacy, and compliance for therapeutic candidates within the nation.

History

Amplia Therapeutics Limited was founded in 2000. The company was formerly known as Innate Immunotherapeutics Limited. The company was incorporated in 2000.

New support ticket

Explore

Amplia Therapeutics Stock Value

Amplia Therapeutics Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Amplia Therapeutics do?

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Amplia Therapeutics Stock Value

Amplia Therapeutics Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Amplia Therapeutics do?

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.